BJP Try Psychiatric Bulletin Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franz, M.
Right arrow Articles by Gallhofer, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franz, M.
Right arrow Articles by Gallhofer, B.

The British Journal of Psychiatry 170: 422-425 (1997)
© 1997 The Royal College of Psychiatrists

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients

M Franz, S Lis, K Pluddemann and B Gallhofer
Centre for Psychiatry, Justus-Liebig University, Giessen, Germany.

BACKGROUND: The effectiveness of antipsychotic drugs against positive psychotic symptoms has been demonstrated in many studies, but their effects on quality of life have yet to be clarified. The impact of different neuroleptic therapies on the subjective quality of life of schizophrenic patients is evaluated in a cross-sectional open study. METHOD: During a four-month period a standardised quality of life interview for schizophrenic patients was applied on day 10 after admission; 33 patients on atypical neuroleptics (AAP) were compared with 31 matched patients on conventional neuroleptics (CAP). RESULTS: The AAP group had significantly higher scores in general quality of life as well as in different life domains: physical well-being, social life and everyday life. In separate comparisons of the AAP group, patients on clozapine and risperidone were found to have a higher quality of life score than patients on CAP or zotepine. CONCLUSIONS: The pharmacological profile of clozapine and risperidone may provide a basis for explaining the higher subjective quality of life found in this study. The lower quality of life of the CAP group may possibly be related to intrinsic effects of the conventional antipsychotics.


This article has been cited by other articles:


Home page
 AJGPHome page
A. O. Bankole, C. I. Cohen, I. Vahia, S. Diwan, M. Kehn, and P. M. Ramirez
Factors Affecting Quality of Life in a Multiracial Sample of Older Persons With Schizophrenia
Am J Geriatr Psychiatry, December 1, 2007; 15(12): 1015 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
S. Hamer and P. M. Haddad
Adverse effects of antipsychotics as outcome measures
The British Journal of Psychiatry, August 1, 2007; 191(50): s64 - s70.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M. Linden, T. Scheel, and F.-X. Eich
Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride
J Psychopharmacol, November 1, 2006; 20(6): 815 - 823.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 6 - 19.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 38 - 56.
[Abstract] [PDF]

Home page
 Psychiatr. Serv.Home page
G. R. Bond, H.-W. Kim, P. S. Meyer, P. J. Gibson, S. Tunis, J. D. Evans, P. Lysaker, M. L. McCoy, J. Dincin, and H. Xie
Response to Vocational Rehabilitation During Treatment With First- or Second-Generation Antipsychotics
Psychiatr Serv, January 1, 2004; 55(1): 59 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
L. de Haan, M. van Bruggen, J. Lavalaye, J. Booij, P. M.A.J. Dingemans, and D. Linszen
Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study
Am J Psychiatry, February 1, 2003; 160(2): 303 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. G. Siris
Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Am J Psychiatry, September 1, 2000; 157(9): 1379 - 1389.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
L. de Haan, J. Lavalaye, D. Linszen, P. M.A.J. Dingemans, and J. Booij
Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patients With Schizophrenia Stabilized by Olanzapine or Risperidone
Am J Psychiatry, June 1, 2000; 157(6): 1019 - 1020.
[Abstract] [Full Text]

Home page
 Int J Soc PsychiatryHome page
A. G. Awad and L. N.P. Voruganti
Quality of Life and New Antipsychotics in Schizophrenia Are Patients Better Off?
International Journal of Social Psychiatry, December 1, 1999; 45(4): 268 - 275.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1997 The Royal College of Psychiatrists.